This website is best viewed using the vertical display on your mobile device.
MMR was achieved in 44% (n=73/167) of patients taking SPRYCEL 100 mg once daily within 7 years1
In the trial, 95% (n=158/167) of patients treated with SPRYCEL 100 mg once daily did not transform to AP or BC1
AP=accelerated phase; BC=blast crisis; CCyR=complete cytogenetic response; CHR=complete hematological response; MCyR=major cytogenetic response; MMR=major molecular response; PI=Prescribing Information; TKI=tyrosine kinase inhibitor; ULN=upper limit of normal; WBC=white blood cell.
*Resistance to imatinib was defined as failure to achieve a complete hematologic response (CHR; after 3 months), major cytogenetic response (MCyR; after 6 months), or complete cytogenetic response (CCyR; after 12 months); or loss of a previous molecular response (with concurrent ≥10% increase in Ph+ metaphases), cytogenetic response, or hematologic response.
†Imatinib intolerance was defined as inability to tolerate 400 mg or more of imatinib per day or discontinuation of imatinib because of toxicity.
‡MCyR combines both complete (0% Ph+ metaphases) and partial (>0%–35%) responses.1
§CHR (response confirmed after 4 weeks): WBC ≤ institutional ULN, platelets <450,000/mm3, no blasts or promyelocytes in peripheral blood, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <20%, and no extramedullary involvement.1
‖CCyR=0% Ph+ metaphases.1